We are live on ! Find out more
MCK icon

McKesson

890.51 USD
-6.14
0.68%
At close Updated Aug 27, 4:00 PM EDT
Pre-market
After hours
890.51
0.00
0%
1 day
-0.68%
5 days
6.03%
1 month
4.76%
3 months
17.72%
6 months
-9.81%
Year to date
8.15%
1 year
30.28%
5 years
342.78%
10 years
384.24%
 

About: McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Employees: 43,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 60.3%
Neutral 29.3%
Negative 10.3%
Positive
Zacks Investment Research
9 hours ago
McKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
McKesson to Acquire Precision Medicine Group to Strengthen Services
Neutral
Zacks Investment Research
2 days ago
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
Positive
Benzinga
2 days ago
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
McKesson Corporation (NYSE:MCK) on Tuesday announced an agreement to acquire Precision Medicine Group.
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
Positive
Reuters
2 days ago
McKesson to buy Precision Medicine Group in about $2.25 billion deal
U.S. drug distributor McKesson said ​on Tuesday it ​would buy clinical research ⁠and biopharma commercialization services ​provider Precision Medicine ​Group in a deal valued at about $2.25 billion.
McKesson to buy Precision Medicine Group in about $2.25 billion deal
Neutral
Business Wire
2 days ago
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. McKesson will acquire Precision Medicine Group for approximately $2.25 billion. Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The transacti.
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
Positive
Zacks Investment Research
3 days ago
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
Positive
Zacks Investment Research
3 days ago
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
Positive
Seeking Alpha
7 days ago
TCW Durable Growth ETF Q2 2026 Performance Update
Net of fees, GRW delivered a return of +17.32% in Q2 2026, compared to the S&P 500 Index's return of +15.20%. The top performers in the quarter were Forgent Power Solutions, Broadcom and Alphabet. The primary detractors in the quarter were McKesson Corporation, Jack Henry & Associates, and LPL Financial.
TCW Durable Growth ETF Q2 2026 Performance Update
Negative
Seeking Alpha
13 days ago
Allspring Large Cap Growth Fund Q2 2026 Performance Update
The fund underperformed the Russell 1000 Growth Index during the quarter. Contributors were Micron Technology, Snowflake, Quanta Services, Arista Networks and Vertiv Holdings. Detractors were McKesson Corp., KLA Corp., Advanced Micro Devices, AstraZeneca and Netflix.
Allspring Large Cap Growth Fund Q2 2026 Performance Update
Positive
Zacks Investment Research
17 days ago
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Price charts implemented using Lightweight Charts™